Zobrazeno 1 - 10
of 970
pro vyhledávání: ''
Autor:
Brian J. Ball, Shukaib Arslan, Paul Koller, Dat Ngo, Michelle Afkhami, Amandeep Salhotra, Monzr Al-Malki, Ahmed Aribi, Haris Ali, Karamjeet Sandhu, Salman Otoukesh, Idoroenyi Amanam, Hoda Pourhassan, Andrew Artz, Peter Curtin, Anthony Stein, Ryotaro Nakamura, Guido Marcucci, Eileen Smith, Vinod Pullarkat, Ibrahim Aldoss
Publikováno v:
Leukemia & Lymphoma. 63:3232-3236
Autor:
Anita Kumar, Carla Casulo, Erel Joffe, Craig Moskowitz, John Gerecitano, Alison Moskowitz, Anas Younes, Pamela Drullinsky, Esther Drill, Morgan Choma, Clare Grieve, Ashlee Joseph, Leana Laraque, Dylan Schick, Andrew Zelenetz, Paul Hamlin
Publikováno v:
Leukemia & Lymphoma. 63:2889-2896
This study evaluated ofatumumab (Ofa), an anti-CD20 monoclonal antibody, alone or with bendamustine (Benda), in transplant-ineligible patients with mantle cell lymphoma. Low-risk patients received Ofa monotherapy. Non-responders received subsequent t
Autor:
Christopher R. Weil, Matthew J. Parsons, Ryan J. Hutten, Felicia H. Lew, Skyler B. Johnson, David K. Gaffney, Randa Tao
Publikováno v:
Leukemia & Lymphoma. 63:2847-2857
Omission of radiotherapy in the upfront management of early-stage classic Hodgkin lymphoma (cHL) has become more common with time. We report patterns of care and outcomes of stage I-II cHL treated with chemotherapy (CT) only versus CT and radiotherap
Publikováno v:
Leukemia & Lymphoma. 63:2905-2911
Although10% of primary CNS lymphoma (PCNSL) patients are ≥80 years, data on this population are limited. We analyzed 19 consecutive octogenarians with PCNSL treated with high-dose methotrexate (HD-MTX)-based chemotherapy at our institution concerni
Autor:
Victor H, Jimenez-Zepeda, Guanmin, Chen, Eileen, Shaw, Megan S, Farris, Tara, Cowling, Jason, Tay
Publikováno v:
Leukemia & Lymphoma. 63:2557-2564
The purpose of this study is to describe the real-world multiple myeloma (MM) population in Alberta by examining patient/clinical characteristics and the treatment landscape. A retrospective, observational study was conducted using province-wide, adm
Autor:
Habte, Yimer, Jason, Melear, Edward, Faber, William I, Bensinger, John M, Burke, Mohit, Narang, Don, Stevens, Kathleen S, Gray, Yana, Lutska, Padma, Bobba, Keqin, Qi, Daniela, Hoehn, Ming, Qi, Thomas S, Lin, Robert M, Rifkin
Publikováno v:
Leukemia & Lymphoma. 63:2383-2392
In the primary analysis of LYRA, daratumumab + cyclophosphamide/bortezomib/dexamethasone (DARA + CyBorD) was effective and well tolerated in newly diagnosed multiple myeloma (NDMM) and relapsed multiple myeloma (RMM). We report the final analysis of
Autor:
Michaël Lévy, Jehan Dupuis, Cecile Charpy, Antoine Martin, Emmanuel Itti, Iradj Sobhani, Corinne Haioun, Aurelien Amiot
Publikováno v:
Leukemia & Lymphoma. 63:2597-2603
To assess the effectiveness and safety of rituximab alone or in combination with chlorambucil for the treatment of translocation (11;18)-negative gastric MALT lymphoma, we included 71 patients in a retrospective case-control study, 54 treated with ri
Autor:
Tamar Berger, Karyn Revital Geiger, Moshe Yeshurun, Anat Gafter‑Gvili, Tzippy Shochat, Ronit Gurion, Pia Raanani, Oren Pasvolsky
Publikováno v:
Leukemia & Lymphoma. 63:2461-2468
Almost half of patients with diffuse large B-cell lymphoma (DLBCL) have relapsed/refractory (R/R) disease after frontline immunochemotherapy. Although guidelines recommend histological confirmation of R/R disease, repeat biopsies are not always perfo
Publikováno v:
Leukemia & Lymphoma. 63:2453-2460
This retrospective single-center study was to evaluate the expression of TCF3 protein in pediatric Burkitt lymphomas (pBLs) and analyze its relations with clinical characteristics and prognosis. A total of 58 pBLs and 30 reactive hyperplastic lymphad
Autor:
Eyal Lebel, Neta Goldschmidt, Tali Siegal, Alexander Lossos, Shai Rosenberg, Chen Makranz, Eduard Linetski, Moshe E. Gatt, Alexander Gural, Revital Saban, David Lavie, Vladimir Vainstein, Eran Zimran, Batia Avni, Sigal Grisaro, Adir Shaulov, Boaz Nachmias
Publikováno v:
Leukemia & Lymphoma. 63:2102-2108
The optimal high-dose methotrexate (HDMTX)-based combination therapy for primary central nervous system lymphoma is unknown. We report our experience with rituximab, HDMTX, procarbazine and lomustine (R-MPL) given as first-line treatment in our cente